1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

US FDA’s Inspection Volume Projected To Return To Normal Levels In FY 2022 As Backlog Looms

 
• By Derrick Gingery

Additional hiring in FDA’s FY 2022 budget request also is expected to help address the inspections delayed by the coronavirus pandemic.

Budget increasing
The FDA requested a 7.9% increase in its overall budget, including a 9.8% increase in budget authority. • Source: Alamy

The US Food and Drug Administration’s drug manufacturing facility inspections are expected to dramatically increase in fiscal year 2022 to more normal levels, but additional funding may be necessary to combat the backlog caused by the coronavirus pandemic.

COVID-related restrictions nearly ground the entire inspection program to a halt in the second half of FY 2020 and most...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

US FDA May Ask Sponsors To Share Data To Help Train AI

 
• By Michael McCaughan

The US FDA may ask sponsors for permission to train AI models using data from new drug applications. Alternatives to animal testing could be a test case.

‘Major Statements’ Are Major Target Of US FDA’s New TV Ad Crackdown

 
• By Sarah Karlin-Smith, Cathy Kelly, and Derrick Gingery

The bolus of untitled letters signals the FDA's approach to enforcement of the final rule on the presentation of the major statement in direct-to-consumer TV ads in a clear, conspicuous and neutral matter.

Why ACIP Could Get Away With Unscientific Actions US FDA Cannot

 
• By Sarah Karlin-Smith

The CDC and its Advisory Committee on Immunization Practices reportedly are planning to make unsubstantiated claims about COVID-19 vaccine adverse events with little recourse for manufacturers and other stakeholders.

Limited Detail In MAHA Strategy Report Could Catch Pharma Off Guard

 
• By Sarah Karlin-Smith

The administration's first actions on drug advertising linked to a new MAHA Strategy report may suggest more specifics about its plans exist than in the limited text of the report.

More from Agency Leadership

Emer Cooke’s EMA Leadership Extended Until 2027 Ahead Of Planned Retirement

 
• By Eliza Slawther

The European Medicines Agency’s executive director Emer Cooke will remain in her post until April 2027, a shorter timeframe than the full five-year term for an executive director’s mandate at the agency, as she will be due to retire.

Limited Detail In MAHA Strategy Report Could Catch Pharma Off Guard

 
• By Sarah Karlin-Smith

The administration's first actions on drug advertising linked to a new MAHA Strategy report may suggest more specifics about its plans exist than in the limited text of the report.

Clinical Trial Approvals In Spain Now 30% Faster For Eligible Phase I Studies

 
• By Francesca Bruce

Spain has widened the pool of Phase I clinical trial applications that are eligible for faster evaluation and approval processes.